Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells.
Induction of immunity to a viral protein that had been transfected into a tumor cell line was studied. The nucleoprotein (NP) of vesicular stomatitis virus (VSV) was used as a model tumor-associated Ag after transfection into EL-4, and H-2b thymoma originating from C57BL/6 mice. The NP-transfected c...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1993
|
| _version_ | 1826260807455866880 |
|---|---|
| author | Kündig, T Bachmann, M Lefrancois, L Puddington, L Hengartner, H Zinkernagel, R |
| author_facet | Kündig, T Bachmann, M Lefrancois, L Puddington, L Hengartner, H Zinkernagel, R |
| author_sort | Kündig, T |
| collection | OXFORD |
| description | Induction of immunity to a viral protein that had been transfected into a tumor cell line was studied. The nucleoprotein (NP) of vesicular stomatitis virus (VSV) was used as a model tumor-associated Ag after transfection into EL-4, and H-2b thymoma originating from C57BL/6 mice. The NP-transfected cell line (EL-4NP) was lysed by NP-specific CTL and was found to restimulate NP-specific CTL in vitro as efficiently as did VSV-infected macrophages. Despite both of these in vitro characteristics, C57BL/6 mice inoculated with EL-4NP did not mount a measurable NP-specific CTL response and developed a lethal tumor as rapidly as did mice given control EL-4. This lack of immunogenicity could not be explained by down-regulation of MHC class I molecules or by loss of NP; even EL-4NP cells metastasizing to the spleen kept their high restimulatory capacity and excellent target characteristics. However, once mice were immunized with VSV or with a vaccinia-VSV-NP recombinant virus they were protected against tumor growth of EL-4NP by CD8+ CTL but not by CD4+ T cells. Taken together, the failure of the tumor-associated Ag to induce a protective T cell response in vivo despite its excellent capacity to restimulate CTL in vitro may encourage adjuvant immunotherapy in cancer; even the effects of weakly immunizing tumor vaccines, e.g., recombinant viruses, may be efficiently amplified by tumor cells. |
| first_indexed | 2024-03-06T19:11:35Z |
| format | Journal article |
| id | oxford-uuid:16f612f1-7753-470d-8739-1b12c090cacb |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:11:35Z |
| publishDate | 1993 |
| record_format | dspace |
| spelling | oxford-uuid:16f612f1-7753-470d-8739-1b12c090cacb2022-03-26T10:34:18ZNonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:16f612f1-7753-470d-8739-1b12c090cacbEnglishSymplectic Elements at Oxford1993Kündig, TBachmann, MLefrancois, LPuddington, LHengartner, HZinkernagel, RInduction of immunity to a viral protein that had been transfected into a tumor cell line was studied. The nucleoprotein (NP) of vesicular stomatitis virus (VSV) was used as a model tumor-associated Ag after transfection into EL-4, and H-2b thymoma originating from C57BL/6 mice. The NP-transfected cell line (EL-4NP) was lysed by NP-specific CTL and was found to restimulate NP-specific CTL in vitro as efficiently as did VSV-infected macrophages. Despite both of these in vitro characteristics, C57BL/6 mice inoculated with EL-4NP did not mount a measurable NP-specific CTL response and developed a lethal tumor as rapidly as did mice given control EL-4. This lack of immunogenicity could not be explained by down-regulation of MHC class I molecules or by loss of NP; even EL-4NP cells metastasizing to the spleen kept their high restimulatory capacity and excellent target characteristics. However, once mice were immunized with VSV or with a vaccinia-VSV-NP recombinant virus they were protected against tumor growth of EL-4NP by CD8+ CTL but not by CD4+ T cells. Taken together, the failure of the tumor-associated Ag to induce a protective T cell response in vivo despite its excellent capacity to restimulate CTL in vitro may encourage adjuvant immunotherapy in cancer; even the effects of weakly immunizing tumor vaccines, e.g., recombinant viruses, may be efficiently amplified by tumor cells. |
| spellingShingle | Kündig, T Bachmann, M Lefrancois, L Puddington, L Hengartner, H Zinkernagel, R Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells. |
| title | Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells. |
| title_full | Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells. |
| title_fullStr | Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells. |
| title_full_unstemmed | Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells. |
| title_short | Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells. |
| title_sort | nonimmunogenic tumor cells may efficiently restimulate tumor antigen specific cytotoxic t cells |
| work_keys_str_mv | AT kundigt nonimmunogenictumorcellsmayefficientlyrestimulatetumorantigenspecificcytotoxictcells AT bachmannm nonimmunogenictumorcellsmayefficientlyrestimulatetumorantigenspecificcytotoxictcells AT lefrancoisl nonimmunogenictumorcellsmayefficientlyrestimulatetumorantigenspecificcytotoxictcells AT puddingtonl nonimmunogenictumorcellsmayefficientlyrestimulatetumorantigenspecificcytotoxictcells AT hengartnerh nonimmunogenictumorcellsmayefficientlyrestimulatetumorantigenspecificcytotoxictcells AT zinkernagelr nonimmunogenictumorcellsmayefficientlyrestimulatetumorantigenspecificcytotoxictcells |